drugset / Trial / NCT00002817

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00002817

Treatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients with metastatic melanoma.

Timeline

Start
1996-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject sargramostim Protein / enzyme biologic
Subject vaccinia-GM-CSF vaccine Vaccine Other

Indications